Sivelestat attenuates perioperative inflammatory response in pediatric heart surgery with cardiopulmonary bypass

Sivelestat attenuates perioperative inflammatory response in pediatric heart surgery with cardiopulmonary bypass - Sivelestat attenuates perioperative inflammatory response in pediatric heart surgery with cardiopulmonary bypass: A prospective randomized study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006598

Enrollment

Registered

2011-10-24

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

congenital heart disease

Interventions

The sivelestat group patients are administrated continuous intravenous infusion of 0.2mg/kg/h of sivelestat, and the control group patients are administrated same volume of 0.9% saline at the initiati

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: consecutive heart surgery with cardiopulmonary bypass, patients are weighting between 5 to 10 kg with

Exclusion criteria

Exclusion criteria: patients with chromosome aberration were excluded

Design outcomes

Primary

Measure	Time frame
white blood cell, neutrophil, polymorphonuclear elastase, C-reactive protein, interleukin-6, interleukin-8, tumor necrosis factor alpha	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026